Valneva SE is a specialty vaccine company that develops manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company applies deep expertise across multiple vaccine modalities to provide first best or only in class vaccine solutions. Valneva SE currently markets three proprietary travel vaccines and has a clinical pipeline that includes the Lyme disease vaccine candidate VLA15 the Shigella vaccine candidate S4V2 and the Zika virus vaccine candidate VLA1601.

Valneva SE generates revenue primarily from the sale of its commercial vaccine portfolio which consists of IXIARO for Japanese encephalitis DUKORAL for cholera and LT ETEC and IXCHIQ for chikungunya. The company also generates revenue from distributing select third party vaccines in countries where it operates its own marketing and sales infrastructure. Revenue is derived from sales to travelers military personnel government customers and private sector clients across its commercial operations in key markets including the United States Canada the United Kingdom Sweden France Austria Norway Denmark Finland Belgium and the Netherlands.

The company operates through the following segments:

• Commercial Portfolio segment which includes the proprietary vaccines IXIARO DUKORAL and IXCHIQ as well as the distribution of third party vaccines such as rabies and hepatitis B vaccines in select markets.

• Research and Development segment which encompasses the clinical pipeline including VLA15 for Lyme disease S4V2 for shigellosis VLA1601 for Zika virus and pre clinical assets targeting Epstein Barr virus and Enterotoxigenic Escherichia coli.

• Manufacturing segment which involves the operation of production facilities in Livingston Scotland Solna Sweden and Vienna Austria to support clinical trial material manufacturing and commercial product fill finish and quality control activities.

Valneva SE holds a differentiated position in the vaccine industry as a specialty provider of travel and niche disease vaccines with no direct competitors for IXIARO in the U. S. Canada and European markets and IXCHIQ being the first licensed chikungunya vaccine in those regions. The company competes against large pharmaceutical and biotechnology firms but leverages strategic partnerships with Pfizer for VLA15 and LimmaTech Biologics AG for S4V2 to access complementary clinical and commercial capabilities. Its competitive advantages include a highly developed manufacturing infrastructure with BSL 3 capabilities a deep scientific and clinical expertise across multiple vaccine modalities and a proven track record of advancing vaccine candidates from early R&D to approval.

Valneva SE serves a diverse customer base that includes travelers to endemic regions military personnel government health agencies such as the U. S. Department of Defense and private sector clients. The company distributes its vaccines through its own commercial operations in key markets and via partnerships with distributors such as Kamada Pharmaceuticals in Canada and Instituto Butantan in Brazil for pilot vaccination campaigns. Specific customer names include the U. S. Department of Defense with which Valneva SE signed a $32 80 million contract in January 2025 for IXIARO.